Halozyme Therapeutics | HALO - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 917.27M 94.89M 2025-09
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amarin USD 458.89M 6.03M 2025-09
Amgen USD 8.66B 961M 2025-12
Baxter International USD 6.13B 1.11B 2025-12
Cara Therapeutics USD 32.93M 41M 2025-06
Cytokinetics USD -659.62M 138.5M 2025-12
DBV Technologies USD 52.85M 33.37M 2025-09
Eli Lilly USD 26.54B 2.74B 2025-12
Esperion Therapeutics USD -451.36M 17.85M 2025-09
Halozyme Therapeutics USD 48.81M 455.1M 2025-12
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
MannKind USD -51.02M 6.47M 2025-12
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Pfizer USD 92.8B 4.11B 2025-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
United Therapeutics USD 7.1B 506M 2025-12
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12